US 12,485,002 B2
Stabilized intraocular drug delivery systems and methods of use
Craig Alan Cable, II, Aliso Viejo, CA (US); Malik Y. Kahook, Denver, CO (US); Glenn R. Sussman, Aliso Viejo, CA (US); and Sean Maass, Aliso Viejo, CA (US)
Assigned to SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, Denver, CO (US)
Filed on Sep. 1, 2023, as Appl. No. 18/459,834.
Application 18/459,834 is a continuation of application No. 17/947,051, filed on Sep. 16, 2022, granted, now 11,771,592.
Application 17/947,051 is a continuation of application No. PCT/US2022/038566, filed on Jul. 27, 2022.
Claims priority of provisional application 63/226,507, filed on Jul. 28, 2021.
Prior Publication US 2023/0404801 A1, Dec. 21, 2023
Int. Cl. A61F 2/16 (2006.01); A61F 9/00 (2006.01)
CPC A61F 2/16 (2013.01) [A61F 2/1613 (2013.01); A61F 2/1648 (2013.01); A61F 9/0017 (2013.01); A61F 2002/1686 (2013.01); A61F 2002/16901 (2015.04); A61F 2250/0067 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An intraocular drug delivery system configured for implantation into an eye of a subject, the intraocular drug delivery system comprising:
an intraocular structure and a drug delivery component;
the intraocular structure comprising an anterior side, a posterior side opposite the anterior side, an edge extending between the posterior side and the anterior side, and a haptic extending outwardly from the edge at an edge-haptic junction, the haptic comprising, at the edge-haptic junction, a relief cut on the posterior side of the intraocular structure; and
the drug delivery component comprising a therapeutic agent and a fixation portion having an opening configured to receive the haptic therethrough, the fixation portion configured to be secured to the relief cut of the haptic such that outward movement of the drug delivery component relative to the edge is inhibited.